Aprea Therapeutics (NASDAQ:APRE) Price Target Lowered to $5.00 at HC Wainwright

Aprea Therapeutics (NASDAQ:APRE) had its price target cut by stock analysts at HC Wainwright from $20.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 442.89% from the stock’s current price.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Aprea Therapeutics Trading Up 1.2%

APRE stock traded up $0.01 during mid-day trading on Thursday, reaching $0.92. The company’s stock had a trading volume of 17,589 shares, compared to its average volume of 51,828. The company has a market cap of $5.81 million, a price-to-earnings ratio of -0.43 and a beta of 1.23. Aprea Therapeutics has a 12 month low of $0.90 and a 12 month high of $5.00. The business’s 50 day moving average price is $1.25 and its 200 day moving average price is $1.52.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The company had revenue of $0.00 million during the quarter. As a group, equities analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Marc Duey bought 21,459 shares of Aprea Therapeutics stock in a transaction dated Wednesday, December 10th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $25,107.03. Following the completion of the purchase, the director directly owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. This trade represents a 9.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 13.63% of the stock is currently owned by company insiders.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.